Balyasny Asset Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Balyasny Asset Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-315,892	Closed	-$100M	–	3244
2023 Q4	$100M	Buy	315,892 +208,093	+193%	+$40.4M	0.19%	108
2023 Q3	$18.2M	Buy	+107,799	New	+$20.3M	0.04%	605
2023 Q2	–	Sell	-7,350	Closed	-$1.34M	–	3018
2023 Q1	$1.34M	Sell	7,350 -24,384	-77%	-$4.66M	﹤0.01%	1632
2022 Q4	$6.24M	Buy	+31,734	New	+$6.8M	0.02%	931
2022 Q3	–	Sell	-72,802	Closed	-$9.21M	–	3370
2022 Q2	$9.21M	Buy	+72,802	New	+$8.37M	0.03%	686

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Balyasny Asset Management's KRTX Position: Q1 2024 in Review

Balyasny Asset Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 315,892 shares — an estimated $100M sold.

Balyasny Asset Management first reported a position in KRTX in Q2 2022 and held it in 5 quarters. The position peaked at $100M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

Balyasny Asset Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Balyasny Asset Management sold 315,892 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $100M.
Balyasny Asset Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
Balyasny Asset Management's Karuna Therapeutics, Inc. Common Stock position peaked at $100M in Q4 2023.
2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Balyasny Asset Management's 13F filing for Q1 2024, filed 13 May 2024.